

SmartPA Criteria Proposal

Drug/Drug Class:	Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit
First Implementation Date:	November 18, 2010
Proposed Date:	September 17, 2020
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of serotonin-norepinephrine reuptake inhibitor (SNRI) agents

Why Issue Selected: MO HealthNet will assess the usage of SNRI agents in the pharmacy program with a primary goal of patient safety. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and without a clinical edit it is almost impossible to prevent duplication within a drug class, dangerous drug interactions, or overmedication. By using medical evidence guidelines, this clinical edit can flag potentially dangerous duplicate and high dose therapy for SNRI agents. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

Program-Specific Information:

Date Range FFS 7-1-2019 to 6-30-2020			
Drug Description	Claims	Spend	Avg spend per claim
VENLAFAXINE HCL	58,079	\$2,996,488.31	\$51.59
MILNACIPRAN HCL	1,822	\$668,178.76	\$368.42
DULOXETINE HCL	89,775	\$2,360,665.18	\$26.29
DESVENLAFAXINE SUCCINATE	11,414	\$486,794.19	\$42.65
DESVENLAFAXINE	93	\$13,016.52	\$138.89
LEVOMILNACIPRAN HCL	2,350	\$952,777.72	\$405.62
Total	163,533	\$7,477,920.68	\$172.24

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Serotonin-norepinephrine reuptake inhibitor (SNRI) agents

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Age range: All appropriate MO HealthNet participants aged 5 years and older

Approval Criteria

- Participant aged 5 years or older **AND**
- Documented compliance to current SNRI therapy regimen (90 days in the past 120 days) **OR**
- Documented appropriate diagnosis required for:
 - Participants < 18 years of age **OR**
 - Participants < 26 years of age who are also enrolled in foster care
- For diagnosis of chronic musculoskeletal pain or diabetic peripheral neuropathic pain – duloxetine agents only
- For diagnosis of fibromyalgia – Cymbalta **or Savella** only

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosage limits (see Appendix A)
- Participants < 18 years of age: history of > 2 SNRI agents for more than 30 days in the past 90 days
- Participants ≥ 18 years of age: history of > 2 SNRI agents for more than 60 days in the past 90 days
- Participant is on more than one SSRI agent and one SNRI agent concurrently for more than 30 days

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception code “0682” (Clinical Edit)
 Rule Type: CE

Default Approval Period

1 year

Appendix A – Maximum Daily Dosage Limits

Generic Equivalent	Max Daily Dose
DESVENLAFAXINE	400 mg
DULOXETINE	120 mg
LEVOMILNACIPRAN ER	120 mg
MILNACIPRAN	200 mg
VENLAFAXINE	375 mg
VENLAFAXINE ER	225 mg

References

- Facts & Comparisons. Serotonin and Norepinephrine Reuptake Inhibitors. Accessed August 5, 2020.

SmartPA Clinical Proposal Form
 © 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.